Durable clinical responses and long-term follow-up of stage III-IV non-small-cell lung cancer (NSCLC) patients treated with IDO peptide vaccine in a phase I study–a …
JW Kjeldsen, TZ Iversen… - Frontiers in …, 2018 - frontiersin.org
Background: Long-term follow-up on a clinical trial of 15 stage III-IV NSCLC patients treated
with an Indoleamine 2, 3-Dioxygenase (IDO) peptide vaccine (NCT01219348). Methods:
Fifteen HLA-A2-positive patients with stable stage III-IV NSCLC after standard chemotherapy …
with an Indoleamine 2, 3-Dioxygenase (IDO) peptide vaccine (NCT01219348). Methods:
Fifteen HLA-A2-positive patients with stable stage III-IV NSCLC after standard chemotherapy …
For custom peptides, please visit www.pepmic.com. Our peptide services including but not limited to:
*Peptide Synthesis: From short peptides to long peptides, linear peptides to cyclic peptides.
*Peptide Modifications: Peptide-protein conjugation, D-amino acid peptides, isotope peptides, fluorescent peptides, multiple antigen peptides, multiple disulfide bridge peptides, phosphopeptides etc.
*Catalog Peptides: ACE Inhibitors, Amyloids & Related Peptides, Antimicrobial Peptides, Apelin Peptides, Myelin Oligodendrocyte Glycoprotein (MOG) Peptides, TAT Proteins etc.
*Peptide Salt: TFA, Desalt, Acetate, HCl.
*Peptide Purity: From crude to >99.5%.
*Production Capacity: From mg to kg, with a capacity of synthesizing 15,000 peptides/month.
*Peptide Library Synthesis: Alanine Scan, Overlapping, Positional Scan, T-cell Truncated, Scrambled ect.
Quick Links:
Contact Information:
Eva He
eva@pepmic.com
Pepmic Co., Ltdeva@pepmic.com
www.pepmic.com
没有评论:
发表评论